The recent surge in capital into niche pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for blockbuster treatments and significant returns is certain, the linked risks are also notable. Many of these e